FORRESTER
18.9.2023 12:01:29 CEST | Business Wire | Press release
Forrester (Nasdaq: FORR) today announced the full conference agenda for Technology & Innovation EMEA, held in London and digitally 12–13 October 2023. As technology finds its way into every function of business, the role of the technology organisation and leader has changed. To stay competitive in today’s business environment, tech leaders need to anticipate the future needs of customers and align critical business capabilities — all underpinned by technology — to help their companies capture value and drive business growth.
At this year’s Technology & Innovation EMEA, chief information officers, chief technology officers, chief digital officers, and other technology leaders will learn best practices to help their organisations prioritise the right decisions, accelerate time to value, and deliver successful outcomes for customers and employees. They will also learn how to leverage emerging technologies such as generative AI to drive innovation and improve efficiency.
The event will include several guest keynote speakers, including noted author, Columbia Business School professor, and founder of the Mentora Institute, Hitendra Wadhwa, and Lloyds Banking Group head of digital delivery and strategy, Mitchell Nova, who will share how new technologies can enhance existing architecture platforms to spark transformation. Technology & Innovation EMEA will also honour EMEA recipients of Forrester’s Technology Awards, which recognise organisations that have successfully implemented technology strategies that are outcome-driven and customer-obsessed to accelerate business growth.
Noteworthy keynotes and sessions include:
- Technology’s Role In Driving The Customer-Obsessed Growth Engine. This keynote discusses how tech executives must work with key stakeholders in their organisation to develop strategies that drive customer value and enable, create, and amplify growth.
- Predictions 2024. Generative AI is exponentially gaining momentum within the future of work, editorial, customer experience, and code writing. In this keynote, learn about the next frontier of innovation threats, advantages, and opportunities in the year ahead.
- The Metaverse Hype Is Over. The Real Work Continues. The metaverse does not exist yet, but precursors do, in consumer- and employee-facing scenarios. This session will discuss how companies are reaching consumers in virtual worlds and how they can make use of new environments for employee onboarding, training, and collaboration.
- Fact Vs. Fiction: When Should You Invest In The Next Shiny Thing? Generative AI already has a key place in the enterprise technology portfolio. This session reveals the current state of the latest emerging technologies, what this means for enterprises, and the lessons that leaders can learn from early adopters of these technologies.
- Digital Leaders Must Become Bolder To Plug Skill Gaps. Every organisation is facing skill gaps when tackling their broader digital transformation initiative. This session will discuss how most European business leaders have difficulty finding the digital talent they need and what they can do to combat this challenge.
“Regardless of the economic climate, technology and innovation is essential to driving business growth,” said Pascal Matzke, event host and VP, research director at Forrester. “Since CIOs and the IT organisation have the broadest span of control and visibility across business, processes, and data systems, they are in the best position to see the big picture and help prioritise initiatives that drive growth. At Technology & Innovation EMEA, tech leaders will learn how to develop resilient, adaptive, and creative strategies that inspire innovation, improve customer experiences, and supercharge business outcomes.”
In-person attendees will experience facilitated discussions, consulting workshops, and special programmes, including the Women’s Leadership Forum; the Executive Leadership Exchange, an exclusive programme targeted at C-level leaders; and several diversity and inclusion sessions. Digital attendees will have access to all conference sessions and sponsors via the event platform.
Resources:
- Register to attend Forrester’s Technology & Innovation EMEA 2023 conference.
- View the full agenda and speakers for Technology & Innovation EMEA 2023.
- Learn about Technology & Innovation EMEA sponsorship opportunities.
- Follow @Forrester and #ForrTech for updates.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the centre of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; 70 million real-time feedback votes; and the shared wisdom of our clients. To learn more, visit Forrester.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230918409305/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom